Orthofix CFO sells shares for tax withholding

Orthofix Medical CFO Julie Andrews reported automatic share sales related to equity compensation.

(Neutral)

(Negative)

Form Type

Rhea-AI Filing Summary

Orthofix Medical CFO Julie Andrews reported automatic share sales related to equity compensation. On March 4 and 5, 2026, she sold a total of 4,788 shares of Orthofix Medical common stock in open‑market transactions at weighted average prices of $12.9163 and $12.5508 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations in connection with the settlement of restricted stock units under a pre‑existing, mandated sell‑to‑cover arrangement approved by the Board’s Compensation and Talent Development Committee, and were executed without her discretion. After these transactions, she directly holds 88,746 shares, including 69,552 restricted stock units.

Insider Trade Summary

Net Seller: 4,788 shares

Net Sell 2 txns

Insider Andrews Julie

Role CFO

Sold 4,788 shs ($61K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,363	$12.5508	$30K
Sale	Common Stock	2,425	$12.9163	$31K

Holdings After Transaction: Common Stock — 88,746 shares (Direct)

Footnotes (4)

F1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
F3. Includes 69,552 previously reported restricted stock units.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

FAQ

What did Orthofix (OFIX) CFO Julie Andrews report in this Form 4?

Orthofix CFO Julie Andrews reported two automatic open-market sales totaling 4,788 common shares. The transactions satisfied tax withholding obligations linked to restricted stock unit settlement under a pre-approved sell-to-cover arrangement mandated by the board’s compensation committee.

How many Orthofix (OFIX) shares did the CFO sell and at what prices?

Julie Andrews sold 2,425 shares at a weighted average price of $12.9163 and 2,363 shares at $12.5508. The filing notes these as weighted averages for multiple trades within narrow intraday price ranges on March 4 and March 5, 2026.

Why were the Orthofix (OFIX) CFO’s shares sold according to the Form 4?

The shares were sold to cover tax withholding obligations from settling restricted stock units. The arrangement was a pre-existing, mandated sell-to-cover program approved by Orthofix’s Compensation and Talent Development Committee, and the filing states the CFO exercised no discretion over the sales.

How many Orthofix (OFIX) shares does the CFO hold after these transactions?

After the reported transactions, Julie Andrews directly holds 88,746 Orthofix common shares. This figure includes 69,552 previously reported restricted stock units, reflecting both settled and outstanding equity awards as disclosed in the ownership footnote.

Were the Orthofix (OFIX) CFO’s stock sales discretionary trades?

No. The filing states the sales were executed under a pre-existing sell-to-cover requirement to satisfy tax withholding obligations. It explicitly notes the sales were made without any exercise of discretion by Julie Andrews regarding timing or amount sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/06/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Andrews Julie

(Last)

(First)

(Middle)

3451 PLANO PARKWAY

(Street)

LEWISVILLE

75056

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Orthofix Medical Inc. [ OFIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/04/2026		S⁽¹⁾		2,425	D	$12.9163⁽²⁾	91,109⁽³⁾	D
Common Stock	03/05/2026		S⁽¹⁾		2,363	D	$12.5508⁽⁴⁾	88,746⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.

3. Includes 69,552 previously reported restricted stock units.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.

	/s/ J. Andres Cedron, Attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR